Article Correctness Is Author's Responsibility: NDA for Transdermal Patch Formulation of Asenapine Submitted to FDA

The article below may contain offensive and/or incorrect content.

An NDA has been submitted to the FDA for a transdermal patch formulation of asenapine for the treatment of schizophrenia.